Skip to main content
SoftOx Solutions AS logo

SoftOx Solutions AS — Investor Relations & Filings

Ticker · SOFTX ISIN · NO0010811961 LEI · 549300AETMWJS91G4A50 OL Manufacturing
Open in API
Filings indexed 572 across all filing types
Latest filing 2021-08-31 Regulatory Filings
Country NO Norway
Listing OL SOFTX

About SoftOx Solutions AS

https://soft-ox.com/

SoftOx Solutions AS is a clinical-stage pharmaceutical company that has developed a patented, non-toxic antimicrobial technology. The technology is based on a stabilized formulation of hypochlorous acid (HOCl), an endogenous molecule used by the human immune system to combat pathogens. It is designed to be highly effective against a broad spectrum of bacteria, viruses, and fungi, and to eradicate and prevent biofilm infections. A key feature of the technology is that its mode of action does not induce antimicrobial resistance (AMR). The company's development pipeline focuses on significant health challenges, with a lead candidate, SoftOx Inhalation Solution (SIS), for treating airway infections, as well as other applications in wound care and disinfection.

Recent filings

Filing Released Lang Actions
SOFTOX SOLUTIONS AS VINNER NASJONALT SYKEHUSANBUD PÅ HÅNDDESINFEKSJON
Regulatory Filings Classification · 100% confidence The document is a short announcement (2826 characters) detailing that SoftOx Solutions AS won a national hospital tender (HINAS) for its hand disinfection product, SafeDes®. It focuses on the outcome of a procurement process and its strategic implications, rather than presenting comprehensive financial results (like 10-K or IR) or detailed management analysis (MDA). It is a specific business development announcement. Since it is not a standard regulatory filing like a 10-K, an earnings release (ER), or a director's dealing (DIRS), and it announces a significant business event (winning a major contract), it fits best under the general 'Regulatory Filings' (RNS) category as a significant, non-standard corporate announcement, or potentially 'Capital/Financing Update' (CAP) if the contract implies immediate revenue/financing impact, but RNS is a safer general category for non-standard news releases. Given the context of winning a major public tender, it is a significant corporate event announcement, which often falls under RNS if no other specific category applies. It is too specific for RNS, but it is not a standard financial report. It is a major business development announcement. Since there is no specific category for 'Tender Win Announcement', RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for significant, non-financial news.
2021-08-31 Norwegian
SoftOx Solutions AS - Prosjekt oppdatering: SoftOx Biofilm Eradicator (SBE)
Regulatory Filings Classification · 99% confidence The document is a short update titled 'Prosjekt oppdatering' (Project Update) regarding the status of a clinical trial (SoftOx Biofilm Eradicator - SBE). It discusses delays due to a nurse strike and outlines the purpose of the Phase 1 study. It is not a full financial report (10-K, IR), an earnings release (ER), or a formal regulatory filing like a DVA or LTR. Given its nature as a specific operational/project status update provided to investors, and its brevity (1391 chars), it fits best as a general announcement or update. Since there is no specific category for 'Project Update' or 'Operational Update', and it is not a formal financial report, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements not covered by the specific codes, or potentially Investor Presentation (IP) if it were more strategic, but this is purely operational news. Given the context of a company providing specific, non-financial operational news, RNS is the safest fallback.
2021-07-19 Norwegian
SoftOx Solutions AS - Project update: SoftOx Biofilm Eradicator (SBE)
Environmental & Social Information Classification · 99% confidence The document is titled 'SoftOx Solutions AS - Project update: SoftOx Biofilm Eradicator (SBE)' and provides an update on a clinical study delay due to a nurses' strike. It is not a formal regulatory filing (like 10-K, IR, ER), nor is it a standard investor presentation or factsheet. It is a specific operational update concerning a product development milestone (Phase I study). Since there is no specific category for 'Project Update' or 'Operational Update', and it is not a standard financial report, it falls best under the general 'Regulatory Filings' (RNS) category as a miscellaneous regulatory announcement or company news release that doesn't fit the other specific codes. The length is short, but it contains substantive news, not just an announcement of another document.
2021-07-19 English
SOFTOX SOLUTIONS AS HAS SUBMITTED A NEW APPLICATION FOR NATIONAL APPROVAL FOR ITS DISINFECTION PRODUCTS
Regulatory Filings Classification · 100% confidence The document is a short announcement regarding a specific operational update: the resubmission of a national approval application for biocidal products in Norway, referencing a previous announcement and providing contact information. It is not a comprehensive financial report (like 10-K or IR), a transcript (CT), or a formal notice of a meeting (DEF 14A/PSI). Since it details a specific, non-financial regulatory/operational event (product approval process) that doesn't fit neatly into the other specific categories (like M&A, Capital Change, or Director Dealing), it best fits the general 'Regulatory Filings' fallback category (RNS) for miscellaneous regulatory announcements.
2021-07-02 English
SOFTOX SOLUTIONS AS HAR LEVERT INN NY SØKNAD OM NASJONAL GODKJENNELSE FOR SINE DESINFEKSJONSPRODUKTER
Regulatory Filings Classification · 100% confidence The document is a short announcement in Norwegian regarding SoftOx Solutions AS submitting a new national approval application for its disinfectant products in Norway, addressing previous objections. It mentions a prior stock exchange announcement and an appeal against a previous rejection. The content focuses on regulatory/legal progress concerning product approval, not financial results, management changes, or standard shareholder information. Given the nature of the announcement—a specific regulatory/legal update regarding product approval processes—it fits best under 'Regulatory Filings' (RNS) as a general regulatory announcement that doesn't align perfectly with the more specific categories like ER, 10-K, or LTR (which usually implies litigation). Since it is a formal announcement about a regulatory submission, RNS is the most appropriate fallback.
2021-07-02 Norwegian
SOFTOX SOLUTIONS AS: SWIS-02 STUDY RESULTS SHOWS SUPERIOR WOUND HEALING
Regulatory Filings Classification · 95% confidence The document is a press release announcing the positive results of a clinical investigation (SWIS-02 study) for a product (SoftOx Wound Irrigation Solution). It details the study's findings (superior wound healing, reduced bacterial burden) and the company's next steps (filing for Medical Device approval in Europe). This type of announcement, focusing on clinical trial outcomes and immediate business implications, is typically classified as an Earnings Release (ER) if it's tied to a reporting period, or more generally as a Regulatory Filing (RNS) if it's a specific operational update that doesn't fit other categories. Since it is a specific announcement of study results that strengthens the platform and precedes regulatory filing, and it is not a full financial report (10-K, IR) or a management discussion (MDA), it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if this was the primary news released during an earnings cycle. Given the focus is purely on R&D/Clinical results and not comprehensive financial performance, RNS is the most appropriate general category for significant, non-standard operational news. However, many companies issue these results as part of their regular reporting cadence. Since it is a direct announcement of a major operational milestone (study completion and positive results), and it is short (3793 chars), it is not a comprehensive report. It is a specific announcement. I will classify it as RNS as it is a general regulatory/operational announcement that doesn't fit the specific financial or management categories.
2021-06-23 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.